Follow
Caleb K Stein
Caleb K Stein
Data Scientist
Verified email at mayo.edu
Title
Cited by
Cited by
Year
Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
L Rasche, SS Chavan, OW Stephens, PH Patel, R Tytarenko, C Ashby, ...
Nature communications 8 (1), 268, 2017
3822017
Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
N Weinhold, C Ashby, L Rasche, SS Chavan, C Stein, OW Stephens, ...
Blood, The Journal of the American Society of Hematology 128 (13), 1735-1744, 2016
2422016
Low expression of hexokinase-2 is associated with false-negative FDG–positron emission tomography in multiple myeloma
L Rasche, E Angtuaco, JE McDonald, A Buros, C Stein, C Pawlyn, ...
Blood, The Journal of the American Society of Hematology 130 (1), 30-34, 2017
2282017
MYC dysregulation in the progression of multiple myeloma
K Misund, N Keane, CK Stein, YW Asmann, G Day, S Welsh, SA Van Wier, ...
Leukemia 34 (1), 322-326, 2020
1522020
Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control
C Pawlyn, MD Bright, AF Buros, CK Stein, Z Walters, LI Aronson, ...
Blood cancer journal 7 (3), e549-e549, 2017
1162017
Removing batch effects from purified plasma cell gene expression microarrays with modified ComBat
CK Stein, P Qu, J Epstein, A Buros, A Rosenthal, J Crowley, G Morgan, ...
BMC bioinformatics 16, 1-9, 2015
1032015
Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker
SS Chavan, J He, R Tytarenko, S Deshpande, P Patel, M Bailey, CK Stein, ...
Blood cancer journal 7 (2), e535-e535, 2017
772017
Clinical value of molecular subtyping multiple myeloma using gene expression profiling
N Weinhold, CJ Heuck, A Rosenthal, S Thanendrarajan, CK Stein, ...
Leukemia 30 (2), 423-430, 2016
762016
Tumor burden limits bispecific antibody efficacy through T-cell exhaustion averted by concurrent cytotoxic therapy
EW Meermeier, SJ Welsh, ME Sharik, MT Du, VM Garbitt, DL Riggs, ...
Blood cancer discovery 2 (4), 354-369, 2021
622021
Artesunate overcomes drug resistance in multiple myeloma by inducing mitochondrial stress and non-caspase apoptosis
X Papanikolaou, S Johnson, T Garg, E Tian, R Tytarenko, Q Zhang, ...
Oncotarget 5 (12), 4118, 2014
522014
Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma
JR Sawyer, E Tian, JD Shaughnessy Jr, J Epstein, CM Swanson, ...
Leukemia 31 (3), 637-644, 2017
402017
Genomic classification and individualized prognosis in multiple myeloma
F Maura, AR Rajanna, B Ziccheddu, AM Poos, A Derkach, K Maclachlan, ...
Journal of Clinical Oncology 42 (11), 1229-1240, 2024
362024
Monosomic loss of MIR15A/MIR16-1 is a driver of multiple myeloma proliferation and disease progression
M Chesi, CK Stein, VM Garbitt, ME Sharik, YW Asmann, M Bergsagel, ...
Blood cancer discovery 1 (1), 68-81, 2020
342020
Identification of PIKfyve kinase as a target in multiple myeloma
CB De Campos, YX Zhu, N Sepetov, S Romanov, LA Bruins, CX Shi, ...
Haematologica 105 (6), 1641, 2019
342019
Dose-dense and less dose-intense total therapy 5 for gene expression profiling-defined high-risk multiple myeloma
Y Jethava, A Mitchell, M Zangari, S Waheed, C Schinke, ...
Blood cancer journal 6 (7), e453-e453, 2016
332016
The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma
CK Stein, C Pawlyn, S Chavan, L Rasche, N Weinhold, A Corken, A Buros, ...
Oncotarget 8 (17), 27854, 2017
312017
Search for rare protein altering variants influencing susceptibility to multiple myeloma
M Scales, D Chubb, SE Dobbins, DC Johnson, N Li, MJ Sternberg, ...
Oncotarget 8 (22), 36203, 2017
152017
ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma
P Neri, BG Barwick, D Jung, JC Patton, R Maity, I Tagoug, CK Stein, ...
Blood cancer discovery 5 (1), 56-73, 2024
142024
Transcriptional heterogeneity overcomes super-enhancer disrupting drug combinations in multiple myeloma
SJ Welsh, BG Barwick, EW Meermeier, DL Riggs, CX Shi, YX Zhu, ...
Blood cancer discovery 5 (1), 34-55, 2024
142024
The clinical impact of macrofocal disease in multiple myeloma differs between presentation and relapse
L Rasche, A Buros, N Weinhold, CK Stein, JE McDonald, SS Chavan, ...
Blood 128 (22), 4431, 2016
92016
The system can't perform the operation now. Try again later.
Articles 1–20